Comorbidity, body mass index, and performance status as prognostic factors in older patients with soft-tissue sarcoma

Introduction: Surgery, chemotherapy, and radiotherapy are the treatments for soft tissue sarcoma (STS) similar to those for other cancers. However, treatment is even more difficult in older patients because of aging-related weakness. The influence of aging-associated factors on prognosis in the patients with STS has not been fully elucidated. This study aimed to clarify the factors that impact prognosis in older patients with STS. Materials and Methods: The present study retrospectively analyzed the data of 262 (?.60 years old) patients with STS. Moreover, this study investigated (1) tumor-associated parameters (e.g., tumor site, tumor size, depth, histological grade [Federation Nationale des Centres de Lutte le Cancer], American joint Committee on Cancer[AJCC, eighth edition] stage, and histotype); (2) treatment-related factors (ie., presence of surgery, neoadjuvant/adjuvant chemotherapy. adjuvant radiotherapy, and surgical margin), and (3) patient-dependent counterparts (e.g., age, gender, performance status [PS], body mass index [BMI], and Charlson comorbidity index (CCI]). Statistical analysis was conducted to evaluate the impact of each factor on overall survival (OS). Results: Among the 262 patients, 217 and 45 were 60-79 and >= 80 years old, respectively. A comparison of the sociodemographic background showed no significant difference other than surgical margin and PS between those groups. According to univariate analysis, the significant factors to impact OS were age, stage, tumor size, depth, surgical margin, PS, BMI, and CCI. Multivariate analysis indicated that advanced stage, poor PS, and low BMI were negative prognostic factors for OS. Intriguingly, multivariate analysis demonstrated that CCI was a not significant factor for OS in this study. Discussion: While AJCC stage is a well-known determinant, this study suggests that physicians should be alerted to poor PS and low BMI in older patients with STS. (C) 2022 Elsevier Ltd. All rights reserved.